Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder

Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20 nig/day in the dose range of 10–30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerabilily and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo.These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.